Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2012 | Research

The role of the 5-hydroxytryptamine pathway in reflux-induced esophageal mucosal injury in rats

Authors: Lingrong Yang, Haifang Cai, Jinfa Tou, Weizhong Gu, Xiaoli Shu, Ting Zhang, Xi Yang, Zheng Shen, Mizu Jiang

Published in: World Journal of Surgical Oncology | Issue 1/2012

Abstract

Background

Dysfunction of the 5-hydroxytryptamine (5-HT) signaling pathway can lead to gastrointestinal motility and secretion abnormalities and to visceral hypersensitivity. The aim of this study is to investigate the role of 5-HT in reflux-induced esophageal mucosal injury.

Methods

Fifty 8-week-old male Sprague-Dawley (SD) rats were randomly divided into a gastroesophageal reflux (GER) model group (30 rats) and a sham surgery control group (20 rats). Four weeks after surgery, the esophageal mucosa was collected for histological evaluation, 5-HT concentrations, and 5-HT selective reuptake transporter (SERT) mRNA and 5-HT₄ receptor (5-HT₄R) protein expressions.

Results

Twenty-seven rats in the GER model group survived, and three rats died. Histologically, in the GER model group, 20 rats had reflux esophagitis (RE group), and 7 rats had non-erosive reflux disease (NERD group). The 5-HT levels in the esophageal tissue from the RE group were significantly higher than those from the control and NERD groups. Both the RE and NERD groups showed significant increases in SERT mRNA expression of the esophageal mucosa than that of the controls, and the SERT mRNA level in the RE group was significantly higher than that in the NERD group. The 5-HT₄R protein level of the esophageal mucosa in the RE group was significantly lower than that in the controls and the NERD group.

Conclusions

We conclude that a 5-HT signaling pathway disorder could be a major factor in the pathogenesis of GER and RE.

Available only for authorised users

Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, Sondheimer J, Staiano A, Thomson M, Veereman-Wauters G, Wenzl TG, North American Society for Pediatric Gastroenterology Hepatology and Nutrition European Society for Pediatric Gastroenterology Hepatology and Nutrition: Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009, 49: 498-547. 10.1097/01.mpg.0000361306.15727.54.CrossRefPubMed

Hassall E: Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr. 2005, 146: S3-S12. 10.1016/j.jpeds.2004.11.034.CrossRefPubMed

Somani SK, Ghoshal UC, Saraswat VA, Aggarwal R, Misra A, Krishnani N, Naik SR: Correlation of esophageal pH and motor abnormalities with endoscopic severity of reflux esophagitis. Dis Esophagus. 2004, 17: 58-62. 10.1111/j.1442-2050.2004.00374.x.CrossRefPubMed

Kostovski A: Long-lasting reflux episodes in gastroesophageal reflux and its complications in children. Hepatogastroenterology. 2003, 50 (Suppl 2): cccix-cccxi.PubMed

Costedio MM, Hyman N, Mawe GM: Serotonin and its role in colonic function and in gastrointestinal disorders. Dis Colon Rectum. 2007, 50: 376-388. 10.1007/s10350-006-0763-3.CrossRefPubMed

Faure C, Patey N, Gauthier C, Brooks EM, Mawe GM: Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology. 2010, 139 (1): 249-258. 10.1053/j.gastro.2010.03.032.PubMedCentralCrossRefPubMed

Tugay M, Yildiz F, Utkan T, Muezzinoglu B, Erden F, Gacar N, Ulak G: Esophagitis impairs esophageal smooth muscle reactivity in the rat model: an in vitro study. Dig Dis Sci. 2003, 48: 2147-2152.CrossRefPubMed

Erbil Y, Turkoglu U, Barbaros U, Balik E, Olgac V, Kaya H, Cimşit B: Oxidative damage in an experimentally induced gastric and gastroduodenal reflux model. Surg Innov. 2005, 12: 219-225. 10.1177/155335060501200306.CrossRefPubMed

Tugtepe H, Tugay M, Bozkurt S, Yildiz F, Utkan T, Yegen BC, Dagli TE: Esophageal smooth muscle reactivity is impaired in chronic reflux esophagitis by both receptor- and nonreceptor-mediated mechanisms. J Pediatr Surg. 2007, 42: 641-646. 10.1016/j.jpedsurg.2006.12.048.CrossRefPubMed

10.

Spiller R: Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil. 2007, 19: 25-31. 10.1111/j.1365-2982.2007.00965.x.CrossRefPubMed

11.

Mader R, Kocher T, Haier J, Wieczorek G, Pfannkuche HJ, Ito M: Investigation of serotonin type 4 receptor expression in human and non-human primate gastrointestinal samples. Eur J Gastroenterol Hepatol. 2006, 18: 945-950. 10.1097/01.meg.0000228975.87645.27.CrossRefPubMed

12.

Hansen MB, Witte AB: The role of serotonin in intestinal luminal sensing and secretion. Acta Physiol (Oxf). 2008, 193: 311-323. 10.1111/j.1748-1716.2008.01870.x.CrossRef

13.

Abdulnour-Nakhoul S, Tobey NA, Nakhoul NL, Wheeler SA, Vanegas X, Orlando RC: The effect of tegaserod on esophageal submucosal glands bicarbonate and mucin secretion. Dig Dis Sci. 2008, 53: 2366-2372. 10.1007/s10620-007-0170-1.CrossRefPubMed

14.

Komada T, Matsuura T, Mikami T, Suzuki K, Sugimoto H, Kimura N, Ohmi T, Toga T, Nakai Y, Eda H, Sakakibara M: Pharmacological characterization and determination of pharmacokinetic and pharmacodynamic relationship of PF-00885706, a novel partial agonist selective for the 5-HT(4) receptor. Pharmacol Res. 2009, 60: 237-246. 10.1016/j.phrs.2009.03.013.CrossRefPubMed

15.

Tonini M, De Giorgio R, De Ponti F: Progress with novel pharmacological strategies for gastro-oesophageal reflux disease. Drugs. 2004, 64: 347-361. 10.2165/00003495-200464040-00001.CrossRefPubMed

16.

Kindt S, Tack J: Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders. Neurogastroenterol Motil. 2007, 19: 32-39. 10.1111/j.1365-2982.2007.00966.x.CrossRefPubMed

17.

Coron E, Hatlebakk JG, Galmiche JP: Medical therapy of gastroesophageal reflux disease. Curr Opin Gastroenterol. 2007, 23: 434-439.PubMed

18.

Beattie DT, Smith JA: Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol. 2008, 377: 181-203. 10.1007/s00210-008-0276-9.CrossRefPubMed

Title: The role of the 5-hydroxytryptamine pathway in reflux-induced esophageal mucosal injury in rats
Authors: Lingrong Yang
Haifang Cai
Jinfa Tou
Weizhong Gu
Xiaoli Shu
Ting Zhang
Xi Yang
Zheng Shen
Mizu Jiang
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-10-219

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The role of the 5-hydroxytryptamine pathway in reflux-induced esophageal mucosal injury in rats

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Laparoscopy-assisted versus open D2 radical gastrectomy for advanced gastric cancer without serosal invasion: a case control study

In vitro and in vivo double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for PC-3 cell line

Primary clear cell adenocarcinoma of the bladder with recurrence: a case report and literature review

Solid variant of aneurysmal bone cyst in the tibia treated with simple curettage without bone graft: a case report

Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival

Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management